Mereo BioPharma Group plc’s MREO share price has dipped by 5.63%, which has investors questioning if this is right time to ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

BRC Therapeutics (BRC), a pharmaceutical company developing proprietary cannabinoid therapeutics, announced today that Dr.

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ...

Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NE ...

It took almost a decade for Aliza Lynch to confirm she had endometriosis despite living with crippling pain that was so bad ...

Truqap can be used in patients whose disease has progressed despite prior endocrine therapy with a CDK 4/6 inhibitor and an aromatase inhibitor, according to a newly published guidance document.

Current second-line options include injectable fulvestrant – sold by AZ as Faslodex and, until now, the only SERD approved for breast cancer in the EU – as well as aromatase inhibitors like ...

You might walk right past it—just another building in downtown Baltimore. But inside the University of Maryland’s Greenebaum ...